What is ABCL stock price today?

ABCL (Abcellera Biologics Inc) stock is trading at $3.45 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ABCL stock going up or down today?

ABCL stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ABCL stock now?

The decision to buy ABCL depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ABCL a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ABCL based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ABCL stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ABCL is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ABCL's P/E ratio?

P/E ratio data for ABCL will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ABCL's market cap?

ABCL (Abcellera Biologics Inc) has a market capitalization of $1.09 billion, making it a small-cap stock.

What is ABCL's price to book ratio?

ABCL trades at a price-to-book (P/B) ratio of 1.14, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ABCL pay dividends?

ABCL does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ABCL's dividend yield?

ABCL does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ABCL stock a good long-term investment?

ABCL's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ABCL's revenue growth rate?

ABCL has shown revenue growth of 7.9% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

ABCL is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in ABCL?

Key risks for ABCL include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ABCL compare to its competitors?

Compare ABCL to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ABCL's performance and positioning.

What is ABCL's stock price target for 2026?

Our AI model provides price targets for ABCL based on fundamental analysis: Bull case $4.49 (+30%), Base case $3.97 (+15%), Bear case $3.11 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ABCL?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ABCL. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ABCL's next earnings report?

ABCL reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ABCL - Abcellera Biologics Inc

NYSE * Health Care * Biotechnology

$3.45

$-0.14 (-3.90%)

About Abcellera Biologics Inc

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

ABCL Key Statistics

Market Cap

$1.09B

P/B Ratio

1.14

EPS

$-0.49

Revenue Growth

+7.9%

Profit Margin

-1.9%

Employees

562

How ABCL Compares to Peers

ABCL has the fastest revenue growth among competitors

ABCL is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ABCL(This stock)	$1.09B	N/A	8%	-1.9%	-
AMGNAmgen Inc	$199.20B	25.8	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.68B	21.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$116.00B	30.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$80.33B	18.5	0%	0.3%	vs REGN
BIIBBiogen Inc	$27.13B	21.4	-0%	0.1%	vs BIIB

Abcellera Biologics Inc Company Information

Headquarters: British Columbia; Canada
Website: www.abcellera.com
Sector: Health Care
Industry: Biotechnology

ABCL - Abcellera Biologics Inc

About Abcellera Biologics Inc

ABCL Key Statistics

How ABCL Compares to Peers

Abcellera Biologics Inc Company Information

ABCL Lician Score

ABCL Financial Snowflake

Upcoming Events for ABCL